Alpha Profiles · Company Profile

Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment.

https://registry.alpha.ac/companies/aktis-oncology-inc

Entity: Public listing published
Primary listing: NASDAQ: AKTS
Verification: Partially verified
Last reviewed: 2026-09-14T14:36:19.726479+00:00

Overview

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metas

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 14, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-09-14T14:36:19.726479+00:00